Literature DB >> 28781025

Changes in Oral Anticoagulant Prescribing for Stroke Prevention in Patients With Atrial Fibrillation.

Endalkachew Admassie1, Leanne Chalmers2, Luke R Bereznicki3.   

Abstract

Suboptimal guideline adherence and underuse of anticoagulants in patients with atrial fibrillation (AF) have been reported worldwide. This study aimed to compare anticoagulation practice in Australia during the pre- and postdirect oral anticoagulant (DOAC) eras. Between January 2011 and July 2015, patients with nonvalvular AF (NVAF) admitted to the Royal Hobart Hospital, Tasmania, Australia, were retrospectively reviewed. The pre- and post-DOAC era cohorts included admissions from January 2011 to July 2013 and August 2013 to July 2015, respectively. Overall, 2,118 patients met our inclusion criteria. The overall rate of anticoagulation increased from 52.5% in the pre-DOAC era to 60.7% in the post-DOAC era (p <0.001). Moreover, prescribing of OACs among high-risk patients improved significantly (63.1% vs 55.2%, p = 0.001). OAC overprescribing in low-risk patients did not change significantly between the 2 cohorts (35.0% vs 42.9% in the pre- and post-DOAC eras, respectively, p = 0.59). In multivariate analysis, DOAC era (odds ratio [OR] 1.40, 95% confidence interval [CI] 1.17 to 1.68 and CHA2DS2-VASc ≥2 (OR 1.95, 95% CI 1.36 to 2.80) were independent predictors of OAC prescribing in both eras and the whole study period. Conversely, aging and previous bleeding were inversely associated with OAC prescribing. In conclusion, there has been a significant increase in OAC prescribing in the post-DOAC era, potentially driven by the widespread availability of DOACs. However, OAC underuse in high-risk patients and overuse in low-risk patients was apparent throughout our study. These findings highlight the need to identify the drivers of anticoagulant underuse and overuse and address them accordingly.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28781025     DOI: 10.1016/j.amjcard.2017.06.055

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

1.  Hospitalization affects the anticoagulation patterns of patients with atrial fibrillation.

Authors:  Anastasios Kartas; Athanasios Samaras; Dimitra Vasdeki; George Dividis; George Fotos; Eleni Paschou; Evropi Forozidou; Paraskevi Tsoukra; Eleni Kotsi; Ioannis Goulas; George Efthimiadis; Gregory Giamouzis; Haralambos Karvounis; Apostolos Tzikas; George Giannakoulas
Journal:  J Thromb Thrombolysis       Date:  2019-08       Impact factor: 2.300

2.  Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.

Authors:  Monika Kozieł; Christine Teutsch; Valentina Bayer; Shihai Lu; Venkatesh K Gurusamy; Jonathan L Halperin; Kenneth J Rothman; Hans-Christoph Diener; Chang-Sheng Ma; Menno V Huisman; Gregory Y H Lip
Journal:  J Arrhythm       Date:  2021-07-10

3.  Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registry.

Authors:  Changsheng Ma; Lionel Riou França; Shihai Lu; Hans-Christoph Diener; Sergio J Dubner; Jonathan L Halperin; Qiang Li; Miney Paquette; Christine Teutsch; Menno V Huisman; Gregory Y H Lip; Kenneth J Rothman
Journal:  J Arrhythm       Date:  2020-03-10

Review 4.  Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities.

Authors:  Masahisa Arahata; Hidesaku Asakura
Journal:  Clin Interv Aging       Date:  2018-09-11       Impact factor: 4.458

5.  Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies.

Authors:  Manuel Anguita; Mariano de la Figuera; Alejandro I Pérez Cabeza; Carmen Suarez Fernández
Journal:  Drugs Context       Date:  2019-10-09

6.  Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study.

Authors:  Woldesellassie M Bezabhe; Luke R Bereznicki; Jan Radford; Barbara C Wimmer; Mohammed S Salahudeen; Ivan Bindoff; Edward Garrahy; Gregory M Peterson
Journal:  J Clin Med       Date:  2020-11-05       Impact factor: 4.241

7.  Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation: the FibStroke study.

Authors:  Aissa Bah; Ilpo Nuotio; Antti Palomäki; Pirjo Mustonen; Tuomas Kiviniemi; Antti Ylitalo; Päivi Hartikainen; K E Juhani Airaksinen; Juha E K Hartikainen
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

8.  Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients With Atrial Fibrillation.

Authors:  Woldesellassie M Bezabhe; Luke R Bereznicki; Jan Radford; Barbara C Wimmer; Colin Curtain; Mohammed S Salahudeen; Gregory M Peterson
Journal:  Front Pharmacol       Date:  2021-03-23       Impact factor: 5.810

9.  Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence.

Authors:  Eyob Alemayehu Gebreyohannes; Sandra Salter; Leanne Chalmers; Luke Bereznicki; Kenneth Lee
Journal:  Am J Cardiovasc Drugs       Date:  2020-12-28       Impact factor: 3.571

10.  Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II.

Authors:  Seil Oh; June-Soo Kim; Yong-Seog Oh; Dong-Gu Shin; Hui-Nam Pak; Gyo-Seung Hwang; Kee-Joon Choi; Jin-Bae Kim; Man-Young Lee; Hyung-Wook Park; Dae-Kyeong Kim; Eun-Sun Jin; Jaeseok Park; Il-Young Oh; Dae-Hee Shin; Hyoung-Seob Park; Jun Hyung Kim; Nam-Ho Kim; Min-Soo Ahn; Bo-Jeong Seo; Young-Joo Kim; Seongsik Kang; Juneyoung Lee; Young-Hoon Kim
Journal:  J Korean Med Sci       Date:  2018-11-21       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.